UNSPSC 51171829: Azasetron hydrochloride

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C17H20ClN3O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BSS7XL60S, chemically known as 2h-1,4-benzoxazine-8-carboxamide, n-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride but generally known as azasetron hydrochloride, which bears US NIH Compound Identifier 115000.

UNSPSC 51171829 Azasetron hydrochloride, a Commodity code, appears in state and local procurement records but shows minimal direct alignment with the pharmaceutical product itself. Recent opportunities tagged under this code actually solicit broad pharmacy services and generic pharmaceutical supply rather than this specific active pharmaceutical ingredient. State and local jurisdictions buying under this code span county corrections departments, state health and human services agencies, and cooperative purchasing alliances serving multiple states. The scope encompasses offender drug testing services (including specimen collection and lab analysis across immunoassay and confirmation methodologies), state-level pharmacy benefit program direct-to-manufacturer contracting, and generic multi-source pharmaceutical and OTC product distribution through authorized wholesalers to government facilities.

Issuing bodies include Collin County Community Supervision and Corrections Department in Texas, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement and serving Oregon and other participating jurisdictions. Geographic activity centers on Texas and the Upper Midwest, with MMCAP's multi-state footprint. Representative recent opportunities include Collin County's RFP 2026-327 for offender specimen collection and drug testing services (response due July 23, 2026, estimated contract value $600,000, two-year term with optional renewals), and the Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026, two-year term with optional extensions). The Texas HHS Commission also issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer pharmacy programs, signaling future formal procurement as the state develops pharmacy benefit strategy.